InflaRx NV (IFRX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov10

InflaRx NV released FY2025 Q3 earnings on November 10 Pre-Market EST, actual revenue USD 27.95 K (forecast USD 34.6 K), actual EPS USD -0.2122 (forecast USD -0.1775)

14:30

InflaRx NV released FY2025 9 Months earnings on November 10 Pre-Market (EST), actual revenue USD 74.1K, actual EPS USD -0.6034

14:30

InflaRx N.V. Reports Positive Data for Anti-inflammatory Drug INF904 Phase 2 Study

12:37

Nov7

InflaRx N.V. to Release Preliminary Results of Oral C5aR Inhibitor INF904 Clinical Trial

21:27

Nov3

InflaRx NV to Release FY2025 Q3 Earnings on November 10, Pre-Market EST, Forecast Revenue USD 34.98K, EPS USD -0.1777

00:05

Oct7

Analyst Schwartz Covers Healthcare Industry Stocks

10:41

Schedules & Filings

Schedules

Filings

Nov10

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 27.95 K, Net Income -14.38 M, EPS -0.2122

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 46.16 K, Net Income -16.87 M, EPS -0.249

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -9 M, EPS -0.1421

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More